GlassScriptPhysician profile
Stefani L Capone
NPI 1891753729
$1,447.27
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $78.58 · 2021: $16.00 · 2022: $311 · 2023: $651 · 2024: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $320.82 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $137.66 | 2019-2024 | Alecensa, Tecentriq, Rozlytrek |
| Pharmacyclics LLC, An Abbvie Company | $118.44 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $112.16 | 2019-2024 | Opdivo |
| Kite Pharma, INC. | $85.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $69.63 | 2022-2023 | |
| Beigene USA, INC. | $56.89 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $56.37 | 2023-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $53.51 | 2022-2023 | |
| Emd Serono, INC. | $51.63 | 2019 | |
| Amgen INC. | $47.76 | 2019-2022 | |
| Janssen Biotech, INC. | $39.51 | 2022 | |
| Csl Behring | $34.75 | 2023 | Afstyla, Idelvion |
| Daiichi Sankyo INC. | $30.94 | 2019-2023 | Enhertu |
| Pfizer INC. | $28.67 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.11 | 2024 | |
| Taiho Oncology, INC. | $25.35 | 2023 | |
| Aurobindo Pharma USA, INC. | $22.59 | 2019-2020 | |
| Genzyme Corporation | $21.36 | 2023 | |
| Astellas Pharma US INC | $20.63 | 2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $19.48 | 2023 | |
| Seagen INC. | $16.44 | 2022 | |
| Blueprint Medicines Corporation | $14.24 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $12.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.93 | 2020 | |
| Adaptive Biotechnologies Corporation | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefani Capone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.